Scholarlink

Background <p>Neonatal sepsis can disrupt brain development through oxidative stress, blood-brain barrier (BBB) dysfunction, peripheral leukocyte infiltration, and white matter injury. N-acetylcysteine (NAC), a glutathione precursor with antioxidant and immunomodulatory properties, is a promising neuroprotective candidate, but its effects in neonatal sepsis-like brain injury remain incompletely defined. The purpose of this study was to investigate whether early NAC pretreatment, followed by continued treatment, was associated with protection in a neonatal LPS model and examine the principal mechanisms associated with its effects.</p> Methods <p>In this study, neonatal C57BL/6J mice received lipopolysaccharide (LPS; 3&#xa0;mg/kg, subcutaneously) on postnatal day (PND) 3 to model sepsis-like injury. NAC was administered intraperitoneally 2&#xa0;h before LPS (200&#xa0;mg/kg), followed by daily treatment (100&#xa0;mg/kg/day) through PND14. Survival was monitored to PND21. Acute outcomes at PND4 included oxidative stress, glial/inflammatory markers, MPO-positive cell accumulation, apoptosis, and BBB-related injury. Longer-term outcomes included myelination, dentate gyrus proliferation, and behavior.</p> Results <p>NAC improved survival after neonatal LPS exposure, with exploratory sex-stratified analyses suggesting greater benefit in males. NAC partially restored cortical glutathione levels and reduced lipid peroxidation, indicating improved redox balance. Although it did not significantly alter galectin-3, GFAP, or NLRP3 at the time point examined, NAC reduced cortical MPO-positive cell burden and attenuated markers associated with neurovascular injury and BBB-associated pathology, including matrix metallopeptidase-9 expression and albumin extravasation. NAC also decreased apoptosis in selected brain regions and partly improved white matter-related outcomes, including oligodendrocyte precursor cell abundance, myelination, and early sensorimotor performance. However, long-term behavioral performance in the open field and novel object recognition tests was not significantly improved at PND60.</p> Conclusions <p>Overall, early NAC pretreatment followed by continued treatment mitigated neonatal LPS-induced sepsis-like brain injury and improved survival, with protection associated with restoration of redox homeostasis and reduction of MPO-positive leukocyte and markers associated with neurovascular injury and BBB-associated pathology rather than broad suppression of measured inflammatory mediators. These findings are consistent with a potential role for a redox-neurovascular-leukocyte pathway in NAC-associated neuroprotection and support further evaluation of NAC in prevention-oriented experimental paradigms relevant to high-risk preterm populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

N-Acetylcysteine protects the developing brain in neonatal sepsis-like inflammation via a redox–neurovascular pathway

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月30日

查看全文
  • Ping Cheng,
  • Shan Zhang,
  • Xiaoli Zhang,
  • Wenhua Li,
  • Mengmeng Du,
  • Mingchao Li,
  • Zengyuan Yu,
  • Jinjin Zhu,
  • Guixiang Zeng,
  • Yiran Xu,
  • Huiqing Sun,
  • Wenqing Kang,
  • Xiaoyang Wang,
  • Changlian Zhu

摘要

Background

Neonatal sepsis can disrupt brain development through oxidative stress, blood-brain barrier (BBB) dysfunction, peripheral leukocyte infiltration, and white matter injury. N-acetylcysteine (NAC), a glutathione precursor with antioxidant and immunomodulatory properties, is a promising neuroprotective candidate, but its effects in neonatal sepsis-like brain injury remain incompletely defined. The purpose of this study was to investigate whether early NAC pretreatment, followed by continued treatment, was associated with protection in a neonatal LPS model and examine the principal mechanisms associated with its effects.

Methods

In this study, neonatal C57BL/6J mice received lipopolysaccharide (LPS; 3 mg/kg, subcutaneously) on postnatal day (PND) 3 to model sepsis-like injury. NAC was administered intraperitoneally 2 h before LPS (200 mg/kg), followed by daily treatment (100 mg/kg/day) through PND14. Survival was monitored to PND21. Acute outcomes at PND4 included oxidative stress, glial/inflammatory markers, MPO-positive cell accumulation, apoptosis, and BBB-related injury. Longer-term outcomes included myelination, dentate gyrus proliferation, and behavior.

Results

NAC improved survival after neonatal LPS exposure, with exploratory sex-stratified analyses suggesting greater benefit in males. NAC partially restored cortical glutathione levels and reduced lipid peroxidation, indicating improved redox balance. Although it did not significantly alter galectin-3, GFAP, or NLRP3 at the time point examined, NAC reduced cortical MPO-positive cell burden and attenuated markers associated with neurovascular injury and BBB-associated pathology, including matrix metallopeptidase-9 expression and albumin extravasation. NAC also decreased apoptosis in selected brain regions and partly improved white matter-related outcomes, including oligodendrocyte precursor cell abundance, myelination, and early sensorimotor performance. However, long-term behavioral performance in the open field and novel object recognition tests was not significantly improved at PND60.

Conclusions

Overall, early NAC pretreatment followed by continued treatment mitigated neonatal LPS-induced sepsis-like brain injury and improved survival, with protection associated with restoration of redox homeostasis and reduction of MPO-positive leukocyte and markers associated with neurovascular injury and BBB-associated pathology rather than broad suppression of measured inflammatory mediators. These findings are consistent with a potential role for a redox-neurovascular-leukocyte pathway in NAC-associated neuroprotection and support further evaluation of NAC in prevention-oriented experimental paradigms relevant to high-risk preterm populations.